| Year |
Citation |
Score |
| 2024 |
Wang S, Klein SO, Urban S, Staudt M, Barthes NPF, Willmann D, Bacher J, Sum M, Bauer H, Peng L, Rennar GA, Gratzke C, Schüle KM, Zhang L, Einsle O, ... ... Jung M, et al. Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity. Nature Communications. 15: 43. PMID 38167811 DOI: 10.1038/s41467-023-44243-6 |
0.33 |
|
| 2023 |
Abdelsalam M, Zmyslia M, Schmidtkunz K, Vecchio A, Hilscher S, Ibrahim HS, Schutkowski M, Jung M, Jessen-Trefzer C, Sippl W. Design and synthesis of bioreductive prodrugs of class I histone deacetylase inhibitors and their biological evaluation in virally transfected acute myeloid leukemia cells. Archiv Der Pharmazie. e2300536. PMID 37932028 DOI: 10.1002/ardp.202300536 |
0.389 |
|
| 2023 |
Sinatra L, Vogelmann A, Friedrich F, Tararina MA, Neuwirt E, Colcerasa A, König P, Toy L, Yesiloglu TZ, Hilscher S, Gaitzsch L, Papenkordt N, Zhai S, Zhang L, Romier C, ... ... Jung M, et al. Development of First-in-Class Dual Sirt2/HDAC6 Inhibitors as Molecular Tools for Dual Inhibition of Tubulin Deacetylation. Journal of Medicinal Chemistry. 66: 14787-14814. PMID 37902787 DOI: 10.1021/acs.jmedchem.3c01385 |
0.762 |
|
| 2023 |
Helmi YY, Papenkordt N, Rennar G, Gbahou F, El-Hady AK, Labani N, Schmidtkunz K, Boettcher S, Jockers R, Abdel-Halim M, Jung M, Zlotos DP. Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Archiv Der Pharmazie. e2300149. PMID 37339785 DOI: 10.1002/ardp.202300149 |
0.308 |
|
| 2023 |
Kohr M, Papenkordt N, Jung M, Kazmaier U. Total synthesis and biological evaluation of histone deacetylase inhibitor WF-3161. Organic & Biomolecular Chemistry. PMID 37194325 DOI: 10.1039/d3ob00641g |
0.322 |
|
| 2022 |
Darwish S, Heimburg T, Ridinger J, Herp D, Schmidt M, Romier C, Jung M, Oehme I, Sippl W. Synthesis, Biochemical, and Cellular Evaluation of HDAC6 Targeting Proteolysis Targeting Chimeras. Methods in Molecular Biology (Clifton, N.J.). 2589: 179-193. PMID 36255625 DOI: 10.1007/978-1-0716-2788-4_12 |
0.35 |
|
| 2022 |
Hassan MM, Sedighi A, Olaoye OO, Häberli C, Merz A, Ramos-Morales E, de Araujo ED, Romier C, Jung M, Keiser J, Gunning PT. Phenotypic Screening of Histone Deacetylase (HDAC) Inhibitors against Schistosoma mansoni. Chemmedchem. e202100622. PMID 35983937 DOI: 10.1002/cmdc.202100622 |
0.324 |
|
| 2022 |
Darwish S, Ghazy E, Heimburg T, Herp D, Zeyen P, Salem-Altintas R, Ridinger J, Robaa D, Schmidtkunz K, Erdmann F, Schmidt M, Romier C, Jung M, Oehme I, Sippl W. Design, Synthesis and Biological Characterization of Histone Deacetylase 8 (HDAC8) Proteolysis Targeting Chimeras (PROTACs) with Anti-Neuroblastoma Activity. International Journal of Molecular Sciences. 23. PMID 35886887 DOI: 10.3390/ijms23147535 |
0.407 |
|
| 2022 |
Glas C, Naydenova E, Lechner S, Wössner N, Yang L, Dietschreit JCB, Sun H, Jung M, Kuster B, Ochsenfeld C, Bracher F. Development of hetero-triaryls as a new chemotype for subtype-selective and potent Sirt5 inhibition. European Journal of Medicinal Chemistry. 240: 114594. PMID 35853430 DOI: 10.1016/j.ejmech.2022.114594 |
0.378 |
|
| 2022 |
Herp D, Ridinger J, Robaa D, Shinsky SA, Schmidtkunz K, Yesiloglu TZ, Bayer T, Steimbach RR, Herbst-Gervasoni CJ, Merz A, Romier C, Sehr P, Gunkel N, Miller AK, Christianson DW, ... ... Jung M, et al. First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies selective inhibitors with cellular target engagement. Chembiochem : a European Journal of Chemical Biology. PMID 35608330 DOI: 10.1002/cbic.202200180 |
0.437 |
|
| 2022 |
Federico S, Khan T, Fontana A, Brogi S, Benedetti R, Sarno F, Carullo G, Pezzotta A, Saraswati AP, Passaro E, Pozzetti L, Papa A, Relitti N, Gemma S, Butini S, ... ... Jung M, et al. Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. European Journal of Medicinal Chemistry. 238: 114409. PMID 35551034 DOI: 10.1016/j.ejmech.2022.114409 |
0.394 |
|
| 2022 |
Zeyen P, Zeyn Y, Herp D, Mahmoudi F, Yesiloglu TZ, Erdmann F, Schmidt M, Robaa D, Romier C, Ridinger J, Herbst-Gervasoni CJ, Christianson DW, Oehme I, Jung M, Krämer OH, et al. Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells. European Journal of Medicinal Chemistry. 234: 114272. PMID 35306288 DOI: 10.1016/j.ejmech.2022.114272 |
0.396 |
|
| 2022 |
Vogelmann A, Jung M, Hansen FK, Schiedel M. Comparison of Cellular Target Engagement Methods for the Tubulin Deacetylases Sirt2 and HDAC6: NanoBRET, CETSA, Tubulin Acetylation, and PROTACs. Acs Pharmacology & Translational Science. 5: 138-140. PMID 35187421 DOI: 10.1021/acsptsci.2c00004 |
0.731 |
|
| 2022 |
Vaca HR, Celentano AM, Toscanini MA, Hauser AT, Macchiaroli N, Cuestas ML, Nusblat AD, Sippl W, Elissondo MC, Jung M, Camicia F, Rosenzvit MC. Identification and characterization of sirtuin enzymes in cestodes and evaluation of sirtuin inhibitors as new cestocidal molecules. International Journal For Parasitology. PMID 35150663 DOI: 10.1016/j.ijpara.2021.12.002 |
0.365 |
|
| 2021 |
Ghazy E, Heimburg T, Lancelot J, Zeyen P, Schmidtkunz K, Truhn A, Darwish S, Simoben CV, Shaik TB, Erdmann F, Schmidt M, Robaa D, Romier C, Jung M, Pierce R, et al. Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis. European Journal of Medicinal Chemistry. 225: 113745. PMID 34392190 DOI: 10.1016/j.ejmech.2021.113745 |
0.345 |
|
| 2021 |
Luise C, Robaa D, Regenass P, Maurer D, Ostrovskyi D, Seifert L, Bacher J, Burgahn T, Wagner T, Seitz J, Greschik H, Park KS, Xiong Y, Jin J, Schüle R, ... ... Jung M, et al. Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors. International Journal of Molecular Sciences. 22. PMID 34072837 DOI: 10.3390/ijms22115910 |
0.306 |
|
| 2021 |
Vaca HR, Celentano AM, Toscanini MA, Heimburg T, Ghazy E, Zeyen P, Hauser AT, Oliveira G, Elissondo MC, Jung M, Sippl W, Camicia F, Rosenzvit MC. The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs. Plos Neglected Tropical Diseases. 15: e0009226. PMID 33657105 DOI: 10.1371/journal.pntd.0009226 |
0.334 |
|
| 2020 |
Hügle M, Regenass P, Warstat R, Hau M, Schmidtkunz K, Lucas X, Wohlwend D, Einsle O, Jung M, Breit B, Günther S. 4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines. Journal of Medicinal Chemistry. PMID 33275431 DOI: 10.1021/acs.jmedchem.0c00478 |
0.312 |
|
| 2020 |
Saraswati AP, Relitti N, Brindisi M, Osko JD, Chemi G, Federico S, Grillo A, Brogi S, McCabe NH, Turkington RC, Ibrahim O, O'Sullivan J, Lamponi S, Ghanim M, Kelly VP, ... ... Jung M, et al. Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. Acs Medicinal Chemistry Letters. 11: 2268-2276. PMID 33214839 DOI: 10.1021/acsmedchemlett.0c00395 |
0.406 |
|
| 2020 |
Relitti N, Saraswati AP, Chemi G, Brindisi M, Brogi S, Herp D, Schmidtkunz K, Saccoccia F, Ruberti G, Ulivieri C, Vanni F, Sarno F, Altucci L, Lamponi S, Jung M, et al. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. European Journal of Medicinal Chemistry. 112998. PMID 33199154 DOI: 10.1016/j.ejmech.2020.112998 |
0.355 |
|
| 2020 |
Glas C, Dietschreit JCB, Wössner N, Urban L, Ghazy E, Sippl W, Jung M, Ochsenfeld C, Bracher F. Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations. European Journal of Medicinal Chemistry. 206: 112676. PMID 32858418 DOI: 10.1016/J.Ejmech.2020.112676 |
0.476 |
|
| 2020 |
Reiner D, Seifert L, Deck C, Schüle R, Jung M, Stark H. Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H receptor for Prader-Willi Syndrome. Scientific Reports. 10: 13558. PMID 32782417 DOI: 10.1038/S41598-020-70523-Y |
0.38 |
|
| 2020 |
Breit B, Lutterbeck M, Liebich A, Keller M, Herp D, Vogelmann A, Jung M, Brosowsky J. Syntheses of Thailandepsin B Pseudo-Natural Products: Access to new highly potent HDAC Inhibitors via Late Stage Modification. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 32725698 DOI: 10.1002/Chem.202002449 |
0.374 |
|
| 2020 |
Schiedel M, Lehotzky A, Szunyogh S, Oláh J, Hammelmann S, Wössner N, Robaa D, Einsle O, Sippl W, Ovádi J, Jung M. HaloTag-targeted Sirtuin rearranging ligand (SirReal) for the development of proteolysis targeting chimeras (PROTACs) against the lysine deacetylase Sirtuin 2 (Sirt2). Chembiochem : a European Journal of Chemical Biology. PMID 32672888 DOI: 10.1002/Cbic.202000351 |
0.723 |
|
| 2020 |
Ghazy E, Zeyen P, Herp D, Hügle M, Schmidtkunz K, Erdmann F, Robaa D, Schmidt M, Morales ER, Romier C, Günther S, Jung M, Sippl W. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. European Journal of Medicinal Chemistry. 200: 112338. PMID 32497960 DOI: 10.1016/J.Ejmech.2020.112338 |
0.5 |
|
| 2020 |
Wössner N, Alhalabi Z, González J, Swyter S, Gan J, Schmidtkunz K, Zhang L, Vaquero A, Ovaa H, Einsle O, Sippl W, Jung M. Sirtuin 1 Inhibiting Thiocyanates (S1th)-A New Class of Isotype Selective Inhibitors of NAD Dependent Lysine Deacetylases. Frontiers in Oncology. 10: 657. PMID 32426286 DOI: 10.3389/Fonc.2020.00657 |
0.451 |
|
| 2020 |
Grathwol CW, Wössner N, Behnisch-Cornwell S, Schulig L, Zhang L, Einsle O, Jung M, Link A. Activation of sirtuin 2 inhibitors employing photoswitchable geometry and aqueous solubility. Chemmedchem. PMID 32314517 DOI: 10.1002/Cmdc.202000148 |
0.446 |
|
| 2020 |
Jung M, Herrlinger EM, Hau M, Redhaber DM, Greve G, Willmann D, Steimle S, Müller M, Lübbert M, Miething CC, Schüle R. Nitroreductase-mediated release of inhibitors of Lysine-Specific Demethylase 1 (LSD1) from prodrugs in transfected acute myeloid leukaemia cells. Chembiochem : a European Journal of Chemical Biology. PMID 32227662 DOI: 10.1002/Cbic.202000138 |
0.419 |
|
| 2020 |
Westphal M, Sant P, Hauser AT, Jung M, Driever W. Chemical Genetics Screen Identifies Epigenetic Mechanisms Involved in Dopaminergic and Noradrenergic Neurogenesis in Zebrafish. Frontiers in Genetics. 11: 80. PMID 32158467 DOI: 10.3389/Fgene.2020.00080 |
0.405 |
|
| 2020 |
Vogelmann A, Robaa D, Sippl W, Jung M. Proteolysis targeting chimeras (PROTACs) for epigenetics research. Current Opinion in Chemical Biology. 57: 8-16. PMID 32146413 DOI: 10.1016/J.Cbpa.2020.01.010 |
0.396 |
|
| 2020 |
Kalinin DV, Jana SK, Pfafenrot M, Chakrabarti A, Melesina J, Shaik TB, Lancelot J, Pierce RJ, Sippl W, Romier C, Jung M, Holl R. Front Cover: Structure‐Based Design, Synthesis, and Biological Evaluation of Triazole‐Based smHDAC8 Inhibitors (ChemMedChem 7/2020) Chemmedchem. 15: 559-559. DOI: 10.1002/Cmdc.201000139 |
0.339 |
|
| 2020 |
Schiedel M, Daub H, Itzen A, Jung M. Front Cover: Validation of the Slow Off‐Kinetics of Sirtuin‐Rearranging Ligands (SirReals) by Means of Label‐Free Electrically Switchable Nanolever Technology (ChemBioChem 8/2020) Chembiochem. 21: 1050-1050. DOI: 10.1002/Cbic.202000190 |
0.657 |
|
| 2019 |
Holl R, Kalinin DV, Jana SK, Pfafenrot M, Chakrabarti A, Melesina J, Shaik TB, Lancelot J, Pierce RJ, Sippl W, Romier C, Jung M. Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors. Chemmedchem. PMID 31816172 DOI: 10.1002/Cmdc.201900583 |
0.489 |
|
| 2019 |
Osko JD, Porter NJ, Reddy PAN, Xiao YC, Rokka J, Jung M, Hooker JM, Salvino JM, Christianson DW. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6. Journal of Medicinal Chemistry. PMID 31793776 DOI: 10.1021/Acs.Jmedchem.9B01540 |
0.444 |
|
| 2019 |
Schiedel M, Daub H, Itzen A, Jung M. Validation of slow off-kinetics of Sirtuin Rearranging Ligands (SirReals) by means of the label-free electrically switchable nanolever technology. Chembiochem : a European Journal of Chemical Biology. PMID 31692222 DOI: 10.1002/Cbic.201900527 |
0.739 |
|
| 2019 |
Saccoccia F, Brindisi M, Gimmelli R, Relitti N, Guidi A, Saraswati AP, Cavella C, Brogi S, Chemi G, Butini S, Papoff G, Senger J, Herp D, Jung M, Campiani G, et al. Screening and phenotypical characterization of Schistosoma mansoni histone deacetylase 8 (SmHDAC8) inhibitors as multi-stage antischistosomal agents. Acs Infectious Diseases. PMID 31661956 DOI: 10.1021/Acsinfecdis.9B00224 |
0.391 |
|
| 2019 |
Grathwol CW, Wössner N, Swyter S, Smith AC, Tapavicza E, Hofstetter RK, Bodtke A, Jung M, Link A. Azologization and repurposing of a hetero-stilbene-based kinase inhibitor: towards the design of photoswitchable sirtuin inhibitors. Beilstein Journal of Organic Chemistry. 15: 2170-2183. PMID 31598174 DOI: 10.3762/Bjoc.15.214 |
0.395 |
|
| 2019 |
Fagan V, Johansson C, Gileadi C, Monteiro O, Dunford JE, Nibhani R, Philpott M, Malzahn J, Wells G, Farham R, Cribbs A, Halidi N, Li F, Chau I, Greschik H, ... ... Jung M, et al. A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function. Journal of Medicinal Chemistry. PMID 31550156 DOI: 10.1021/Acs.Jmedchem.9B00562 |
0.369 |
|
| 2019 |
Monaldi D, Rotili D, Lancelot J, Marek M, Wössner N, Lucidi A, Tomaselli D, Ramos-Morales E, Romier C, Pierce R, Mai A, Jung M. Structure-Reactivity Relationships on Substrates and Inhibitors of the Lysine Deacylase Sirtuin 2 from Schistosoma Mansoni (SmSirt2). Journal of Medicinal Chemistry. PMID 31496251 DOI: 10.1021/Acs.Jmedchem.9B00638 |
0.466 |
|
| 2019 |
Malecki PH, Rueger N, Roatsch M, Krylova O, Link A, Jung M, Heinemann U, Weiss MS. Structure-based screening of tetrazolylhydrazide inhibitors vs. KDM4 histone demethylases. Chemmedchem. PMID 31475772 DOI: 10.1002/Cmdc.201900441 |
0.481 |
|
| 2019 |
Roatsch M, Hoffmann I, Abboud MI, Hancock RL, Tarhonskaya H, Hsu KF, Wilkins SE, Yeh TL, Lippl K, Serrer K, Moneke I, Ahrens TD, Robaa D, Wenzler S, Barthes NPF, ... ... Jung M, et al. The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases. Acs Chemical Biology. PMID 31287655 DOI: 10.1021/Acschembio.9B00289 |
0.472 |
|
| 2019 |
Xiong Y, Greschik H, Johansson C, Seifert L, Bacher J, Park KS, Babault N, Martini ML, Fagan V, Li F, Chau I, Christott T, Dilworth D, Barsyte-Lovejoy D, Vedadi M, ... ... Jung M, et al. Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1). Journal of Medicinal Chemistry. PMID 31260300 DOI: 10.1021/Acs.Jmedchem.9B00522 |
0.372 |
|
| 2019 |
Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca BT, Hermann B, Maurer J, Greschik H, ... ... Jung M, et al. KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells. Nature Structural & Molecular Biology. PMID 31061526 DOI: 10.1038/S41594-019-0219-9 |
0.368 |
|
| 2019 |
Soares Romeiro LA, da Costa Nunes JL, de Oliveira Miranda C, Simões Heyn Roth Cardoso G, de Oliveira AS, Gandini A, Kobrlova T, Soukup O, Rossi M, Senger J, Jung M, Gervasoni S, Vistoli G, Petralla S, Massenzio F, et al. Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease. Acs Medicinal Chemistry Letters. 10: 671-676. PMID 30996816 DOI: 10.1021/Acsmedchemlett.9B00071 |
0.357 |
|
| 2019 |
Link A, Vojacek S, Schulig L, Wössner N, Geist N, Langel W, Jung M, Schade D. Tetrahydroindoles as Multipurpose Screening Compounds and Novel Sirtuin Inhibitors. Chemmedchem. PMID 30811852 DOI: 10.1002/Cmdc.201900054 |
0.409 |
|
| 2019 |
Simon RP, Rumpf T, Linkuvienė V, Matulis D, Akhtar A, Jung M. Cofactor Analogues as Active Site Probes in Lysine Acetyltransferases. Journal of Medicinal Chemistry. PMID 30785747 DOI: 10.1021/Acs.Jmedchem.8B01887 |
0.424 |
|
| 2019 |
Barth J, Abou-El-Ardat K, Dalic D, Kurrle N, Maier AM, Mohr S, Schütte J, Vassen L, Greve G, Schulz-Fincke J, Schmitt M, Tosic M, Metzger E, Bug G, Khandanpour C, ... ... Jung M, et al. LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML. Leukemia. PMID 30679800 DOI: 10.1038/S41375-018-0375-7 |
0.352 |
|
| 2019 |
Vögerl K, Ong N, Senger J, Herp D, Schmidtkunz K, Marek M, Müller M, Bartel K, Shaik TB, Porter NJ, Robaa D, Christianson DW, Romier C, Sippl W, Jung M, et al. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 (HDAC6) Inhibitors. Journal of Medicinal Chemistry. PMID 30645113 DOI: 10.1021/Acs.Jmedchem.8B01090 |
0.513 |
|
| 2019 |
Muth M, Jänsch N, Kopranovic A, Krämer A, Wössner N, Jung M, Kirschhöfer F, Brenner-Weiß G, Meyer-Almes FJ. Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine. Biochimica Et Biophysica Acta. General Subjects. PMID 30611847 DOI: 10.2210/Pdb6Gjk/Pdb |
0.421 |
|
| 2019 |
Franz F, Jechle H, Wilde M, Angerer V, Huppertz LM, Longworth M, Kassiou M, Jung M, Auwärter V. Structure-metabolism relationships of valine and tert -leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry Forensic Toxicology. 37: 316-329. DOI: 10.1007/S11419-018-00462-X |
0.311 |
|
| 2019 |
Małecki PH, Rüger N, Roatsch M, Krylova O, Link A, Jung M, Heinemann U, Weiss MS. Front Cover: Structure‐Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases (ChemMedChem 21/2019) Chemmedchem. 14: 1803-1803. DOI: 10.1002/Cmdc.201900598 |
0.431 |
|
| 2018 |
Marek M, Shaik TB, Heimburg T, Chakrabarti A, Lancelot J, Ramos Morales E, Da Veiga C, Kalinin DV, Melesina J, Robaa D, Schmidtkunz K, Suzuki T, Holl R, Ennifar E, Pierce R, ... Jung M, et al. Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants. Journal of Medicinal Chemistry. PMID 30347148 DOI: 10.2210/Pdb6Htt/Pdb |
0.474 |
|
| 2018 |
Brindisi M, Senger J, Cavella C, Grillo A, Chemi G, Gemma S, Cucinella DM, Lamponi S, Sarno F, Iside C, Nebbioso A, Novellino E, Shaik TB, Romier C, Herp D, ... Jung M, et al. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. European Journal of Medicinal Chemistry. 157: 127-138. PMID 30092367 DOI: 10.1016/J.Ejmech.2018.07.069 |
0.469 |
|
| 2018 |
Ginsel C, Plitzko B, Froriep D, Stolfa DA, Jung M, Kubitza C, Scheidig AJ, Havemeyer A, Clement B. The Involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the Reductive Metabolism of Hydroxamic Acids. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 30045842 DOI: 10.1124/Dmd.118.082453 |
0.336 |
|
| 2018 |
Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Müller M, Bayer T, Sippl W, Jung M, Gunkel N, Miller AK, Westermann F, Witt O, Oehme I. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. Archives of Toxicology. PMID 29947893 DOI: 10.1007/S00204-018-2234-8 |
0.418 |
|
| 2018 |
Robaa D, Monaldi D, Wössner N, Norio, Kudo, Rumpf T, Schiedel M, Yoshida M, Jung M. Opening the Selectivity Pocket in the Human Lysine Deacetylase Sirtuin2 - New Opportunities, New Questions. Chemical Record (New York, N.Y.). PMID 29931800 DOI: 10.1002/Tcr.201800044 |
0.757 |
|
| 2018 |
Simeth NA, Altmann LM, Woessner N, Bauer E, Jung M, König B. Photochromic Indolyl Fulgimides as Chromo-Pharmacophores Targeting Sirtuins. The Journal of Organic Chemistry. PMID 29852733 DOI: 10.1021/Acs.Joc.8B00795 |
0.363 |
|
| 2018 |
Bayer T, Chakrabarti A, Lancelot J, Shaik TB, Hausmann K, Melesina J, Schmidtkunz K, Marek M, Erdmann F, Schmidt M, Robaa D, Romier C, Pierce RJ, Jung M, Sippl W. Synthesis, crystallization studies and in vitro characterization of novel cinnamic acid derivatives as SmHDAC8 inhibitors for the treatment of Schistosomiasis. Chemmedchem. PMID 29806110 DOI: 10.1002/Cmdc.201800238 |
0.449 |
|
| 2018 |
Lecointre B, Narozny R, Borrello MT, Senger J, Chakrabarti A, Jung M, Marek M, Romier C, Melesina J, Sippl W, Bischoff L, Ganesan A. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 373. PMID 29685969 DOI: 10.1098/Rstb.2017.0364 |
0.495 |
|
| 2018 |
Swyter S, Schiedel M, Monaldi D, Szunyogh S, Lehotzky A, Rumpf T, Ovádi J, Sippl W, Jung M. New chemical tools for probing activity and inhibition of the NAD-dependent lysine deacylase sirtuin 2. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 373. PMID 29685963 DOI: 10.1098/Rstb.2017.0083 |
0.764 |
|
| 2018 |
Daskalakis M, Brocks D, Sheng YH, Islam MS, Ressnerova A, Assenov Y, Milde T, Oehme I, Witt O, Goyal A, Kühn A, Hartmann M, Weichenhan D, Jung M, Plass C. Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors. Cell Cycle (Georgetown, Tex.). 1-31. PMID 29633898 DOI: 10.1080/15384101.2018.1442623 |
0.413 |
|
| 2018 |
Hauser AT, Robaa D, Jung M. Epigenetic small molecule modulators of histone and DNA methylation. Current Opinion in Chemical Biology. 45: 73-85. PMID 29579619 DOI: 10.1016/J.Cbpa.2018.03.003 |
0.393 |
|
| 2018 |
Shen J, Najafi S, Stäble S, Fabian J, Koeneke E, Kolbinger FR, Wrobel JK, Meder B, Distel M, Heimburg T, Sippl W, Jung M, Peterziel H, Kranz D, Boutros M, et al. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell Death and Differentiation. PMID 29515255 DOI: 10.1038/S41418-018-0080-0 |
0.413 |
|
| 2018 |
Simoben CV, Robaa D, Chakrabarti A, Schmidtkunz K, Marek M, Lancelot J, Kannan S, Melesina J, Shaik TB, Pierce RJ, Romier C, Jung M, Sippl W. A Novel Class of Schistosoma mansoni Histone Deacetylase 8 (HDAC8) Inhibitors Identified by Structure-Based Virtual Screening and In Vitro Testing. Molecules (Basel, Switzerland). 23. PMID 29498707 DOI: 10.3390/Molecules23030566 |
0.469 |
|
| 2018 |
Karaman B, Alhalabi Z, Swyter S, Mihigo SO, Andrae-Marobela K, Jung M, Sippl W, Ntie-Kang F. Identification of Bichalcones as Sirtuin Inhibitors by Virtual Screening and In Vitro Testing. Molecules (Basel, Switzerland). 23. PMID 29443909 DOI: 10.3390/Molecules23020416 |
0.421 |
|
| 2018 |
King K, Hauser AT, Melesina J, Sippl W, Jung M. Carbamates as Potential Prodrugs and a New Warhead for HDAC Inhibition. Molecules (Basel, Switzerland). 23. PMID 29393896 DOI: 10.3390/Molecules23020321 |
0.503 |
|
| 2018 |
Bayer T, Chakrabarti A, Lancelot J, Shaik TB, Hausmann K, Melesina J, Schmidtkunz K, Marek M, Erdmann F, Schmidt M, Robaa D, Romier C, Pierce RJ, Jung M, Sippl W. Front Cover: Synthesis, Crystallization Studies, and in vitro Characterization of Cinnamic Acid Derivatives as Sm
HDAC8 Inhibitors for the Treatment of Schistosomiasis (ChemMedChem 15/2018) Chemmedchem. 13: 1488-1488. DOI: 10.1002/Cmdc.201800494 |
0.371 |
|
| 2017 |
Schiedel M, Fallarero A, Luise C, Sippl W, Vuorela P, Jung M. Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Medchemcomm. 8: 465-470. PMID 30108764 DOI: 10.1039/C6Md00647G |
0.745 |
|
| 2017 |
Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T, Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R, ... Jung M, et al. Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation. European Journal of Medicinal Chemistry. 144: 52-67. PMID 29247860 DOI: 10.1016/J.Ejmech.2017.12.001 |
0.442 |
|
| 2017 |
Szabó A, Oláh J, Szunyogh S, Lehotzky A, Szénási T, Csaplár M, Schiedel M, Lőw P, Jung M, Ovádi J. Modulation Of Microtubule Acetylation By The Interplay Of TPPP/p25, SIRT2 And New Anticancer Agents With Anti-SIRT2 Potency. Scientific Reports. 7: 17070. PMID 29213065 DOI: 10.1038/S41598-017-17381-3 |
0.709 |
|
| 2017 |
Heimburg T, Kolbinger FR, Zeyen P, Ghazy E, Herp D, Schmidtkunz K, Melesina J, Shaik TB, Erdmann F, Schmidt M, Romier C, Robaa D, Witt O, Oehme I, Jung M, et al. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity. Journal of Medicinal Chemistry. PMID 29190092 DOI: 10.1021/Acs.Jmedchem.7B01447 |
0.516 |
|
| 2017 |
Wünsch M, Senger J, Schultheisz P, Schwarzbich S, Schmidtkunz K, Michalek C, Klaß M, Goskowitz S, Borchert P, Praetorius L, Sippl W, Jung M, Sewald N. Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors. Chemmedchem. PMID 29120081 DOI: 10.1002/Cmdc.201700550 |
0.497 |
|
| 2017 |
Tsai WB, Long Y, Chang JT, Savaraj N, Feun LG, Jung M, Chen HHW, Kuo MT. Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1α Degradation at the ASS1 promoter for ASS1 Derepression. Scientific Reports. 7: 10814. PMID 28883660 DOI: 10.1038/S41598-017-11445-0 |
0.376 |
|
| 2017 |
Hügle M, Lucas X, Ostrovskyi D, Regenass P, Gerhardt S, Einsle O, Hau M, Jung M, Breit B, Günther S, Wohlwend D. Beyond the BET family: targeting CBP/p300 with 4-acyl pyrroles. Angewandte Chemie (International Ed. in English). PMID 28766825 DOI: 10.1002/Anie.201705516 |
0.399 |
|
| 2017 |
Stenzel K, Chakrabarti A, Melesina J, Hansen FK, Lancelot J, Herkenhöhner S, Lungerich B, Marek M, Romier C, Pierce RJ, Sippl W, Jung M, Kurz T. Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni. Archiv Der Pharmazie. PMID 28639720 DOI: 10.1002/Ardp.201700096 |
0.493 |
|
| 2017 |
Stenzel K, Hamacher A, Hansen FK, Gertzen CGW, Senger J, Marquardt V, Marek L, Marek M, Romier C, Remke M, Jung M, Gohlke H, Kassack MU, Kurz T. Alkoxyurea-based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines. Journal of Medicinal Chemistry. PMID 28581289 DOI: 10.1021/Acs.Jmedchem.6B01538 |
0.401 |
|
| 2017 |
Krieger V, Hamacher A, Gertzen CGW, Senger J, Zwinderman MRH, Marek M, Romier C, Dekker FJ, Kurz T, Jung M, Gohlke H, Kassack MU, Hansen FK. Design, multicomponent synthesis and anticancer activity of a focused histone deacetylase (HDAC) inhibitor library with peptoid-based cap groups. Journal of Medicinal Chemistry. PMID 28574690 DOI: 10.1021/Acs.Jmedchem.7B00197 |
0.48 |
|
| 2017 |
Vojacek S, Beese K, Alhalabi Z, Swyter S, Bodtke A, Schulzke C, Jung M, Sippl W, Link A. Three-Component Aminoalkylations Yielding Dihydronaphthoxazine-Based Sirtuin Inhibitors: Scaffold Modification and Exploration of Space for Polar Side-Chains. Archiv Der Pharmazie. PMID 28547816 DOI: 10.1002/Ardp.201700097 |
0.413 |
|
| 2017 |
Wutz D, Gluhacevic D, Chakrabarti A, Schmidtkunz K, Robaa D, Erdmann F, Romier C, Sippl W, Jung M, König B. Photochromic histone deacetylase inhibitors based on dithienylethenes and fulgimides. Organic & Biomolecular Chemistry. PMID 28537315 DOI: 10.1039/C7Ob00976C |
0.506 |
|
| 2017 |
Schiedel M, Herp D, Hammelmann S, Swyter S, Lehotzky A, Robaa D, Olah J, Ovádi J, Sippl W, Jung M. Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). Journal of Medicinal Chemistry. PMID 28379698 DOI: 10.1021/Acs.Jmedchem.6B01872 |
0.737 |
|
| 2017 |
Schiedel M, Robaa D, Rumpf T, Sippl W, Jung M. The Current State of NAD(+) -Dependent Histone Deacetylases (Sirtuins) as Novel Therapeutic Targets. Medicinal Research Reviews. PMID 28094444 DOI: 10.1002/Med.21436 |
0.743 |
|
| 2017 |
Hau M, Zenk F, Ganesan A, Iovino N, Jung M. Cellular analysis of the action of epigenetics drugs and probes. Epigenetics. 0. PMID 28071961 DOI: 10.1080/15592294.2016.1274472 |
0.415 |
|
| 2017 |
Müller SJ, Wider D, Thomsen AR, Follo M, Waldschmidt JM, Ihorst G, Dold SM, Felthaus J, Senger J, Schüler J, Duyster J, Azab AK, Hug MJ, Jung M, Wäsch R, et al. Epigenetic Modifications of the Bone Marrow (BM) Niche in Multiple Myeloma (MM) - a Three-Dimensional (3D) in Vitro Approach Blood. 130: 1793-1793. DOI: 10.1182/Blood.V130.Suppl_1.1793.1793 |
0.345 |
|
| 2017 |
Barth J, Scheder A, Mohr S, Schulz-Fincke J, Schmitt M, Walter A, Tosic M, Metzger E, Bug G, Lübbert M, Jung M, Serve H, Schüle R, Berg T. LSD1 Inhibition Leads to Differentiation in Hoxa9/Meis1- but Not in MN1-Induced Acute Myeloid Leukemia Blood. 130: 1246-1246. DOI: 10.1182/Blood.V130.Suppl_1.1246.1246 |
0.315 |
|
| 2017 |
Ong DN, Dittrich S, Swyter S, Jung M, Bracher F. Synthesis of highly substituted 3-arylideneindolin-2-ones Tetrahedron. 73: 5668-5679. DOI: 10.1016/J.Tet.2017.08.005 |
0.308 |
|
| 2016 |
Marek M, Shaik TB, Jung M, Sippl W, Pierce RJ, Romier C. Biologie Aujourd'Hui. 210: 311-320. PMID 28327287 DOI: 10.1051/Jbio/2017001 |
0.435 |
|
| 2016 |
Schiffmann I, Greve G, Jung M, Lübbert M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics. 0. PMID 27846368 DOI: 10.1080/15592294.2016.1237345 |
0.358 |
|
| 2016 |
Pan D, Kather M, Willmann L, Schlimpert M, Bauer C, Lagies S, Schmidtkunz K, Eisenhardt SU, Jung M, Günther S, Kammerer B. Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7. International Journal of Molecular Sciences. 17. PMID 27783056 DOI: 10.3390/Ijms17101772 |
0.307 |
|
| 2016 |
Robaa D, Wagner T, Luise C, Carlino L, McMillan J, Flaig R, Schüle R, Jung M, Sippl W. Identification and Structure-Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1. Chemmedchem. PMID 27634332 DOI: 10.1002/Cmdc.201600362 |
0.471 |
|
| 2016 |
Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E, Bauer SM, Schmidtkunz K, Wenzler S, Metzger E, Kuster B, ... ... Jung M, et al. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). Future Medicinal Chemistry. PMID 27572962 DOI: 10.4155/Fmc-2016-0132 |
0.445 |
|
| 2016 |
Chakrabarti A, Melesina J, Kolbinger FR, Oehme I, Senger J, Witt O, Sippl W, Jung M. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Medicinal Chemistry. PMID 27572818 DOI: 10.4155/Fmc-2016-0117 |
0.487 |
|
| 2016 |
Brindisi M, Cavella C, Brogi S, Nebbioso A, Senger J, Maramai S, Ciotta A, Iside C, Butini S, Lamponi S, Novellino E, Altucci L, Jung M, Campiani G, Gemma S. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Future Medicinal Chemistry. PMID 27556815 DOI: 10.4155/Fmc-2016-0068 |
0.474 |
|
| 2016 |
Morera L, Roatsch M, Fürst MC, Hoffmann I, Senger J, Hau M, Franz H, Schüle R, Heinrich MR, Jung M. 4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A. Chemmedchem. PMID 27505861 DOI: 10.1002/Cmdc.201600218 |
0.493 |
|
| 2016 |
Slynko I, Schmidtkunz K, Rumpf T, Klaeger S, Heinzlmeir S, Najar A, Metzger E, Kuster B, Schüle R, Jung M, Sippl W. Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing. Chemmedchem. PMID 27472906 DOI: 10.1002/Cmdc.201600284 |
0.419 |
|
| 2016 |
Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics. 8: 57. PMID 27222667 DOI: 10.1186/S13148-016-0223-4 |
0.397 |
|
| 2016 |
Hügle M, Lucas X, Weitzel G, Ostrovskyi D, Breit B, Gerhardt S, Schmidtkunz K, Jung M, Schüle R, Einsle O, Günther S, Wohlwend D. Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes. Data in Brief. 7: 1370-4. PMID 27158652 DOI: 10.1016/J.Dib.2016.04.009 |
0.316 |
|
| 2016 |
Roatsch M, Robaa D, Pippel M, Nettleship JE, Reddivari Y, Bird LE, Hoffmann I, Franz H, Owens RJ, Schüle R, Flaig R, Sippl W, Jung M. Substituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylases. Future Medicinal Chemistry. PMID 26971619 DOI: 10.4155/Fmc.15.188 |
0.454 |
|
| 2016 |
Heimburg T, Chakrabarti A, Lancelot J, Marek M, Melesina J, Hauser AT, Shaik TB, Duclaud S, Robaa D, Erdmann F, Schmidt M, Romier C, Pierce RJ, Jung M, Sippl W. Structure-Based Design and Synthesis of Novel Inhibitors targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis. Journal of Medicinal Chemistry. PMID 26937828 DOI: 10.1021/Acs.Jmedchem.5B01478 |
0.477 |
|
| 2016 |
Galleano I, Schiedel M, Jung M, Madsen AS, Olsen CA. Correction to A Continuous, Fluorogenic Sirtuin 2 Deacylase Assay: Substrate Screening and Inhibitor Evaluation. Journal of Medicinal Chemistry. 59: 2847. PMID 26936455 DOI: 10.1021/Acs.Jmedchem.6B00239 |
0.705 |
|
| 2016 |
Wagner T, Greschik H, Burgahn T, Schmidtkunz K, Schott AK, McMillan J, Baranauskienė L, Xiong Y, Fedorov O, Jin J, Oppermann U, Matulis D, Schüle R, Jung M. Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform. Nucleic Acids Research. PMID 26893353 DOI: 10.1093/Nar/Gkw089 |
0.437 |
|
| 2016 |
Galleano I, Schiedel M, Jung M, Madsen AS, Olsen CA. A Continuous, Fluorogenic Sirtuin 2 Deacylase Assay: Substrate Screening and Inhibitor Evaluation. Journal of Medicinal Chemistry. 59: 1021-31. PMID 26788965 DOI: 10.1021/Acs.Jmedchem.5B01532 |
0.753 |
|
| 2016 |
Schiedel M, Rumpf T, Karaman B, Lehotzky A, Gerhardt S, Ovádi J, Sippl W, Einsle O, Jung M. Structure-Based Development of an Affinity Probe for Sirtuin 2. Angewandte Chemie (International Ed. in English). PMID 26748890 DOI: 10.1002/Anie.201509843 |
0.745 |
|
| 2016 |
Barth J, Scheder A, Mohr S, Johannes S, Schmitt M, Walter A, Tosic M, Metzger E, Lübbert M, Jung M, Serve H, Schüle R, Berg T. LSD1 Inhibition Induces Differentiation and Reduces the Frequency of Leukemia-Initiating Cells in Hoxa9/Meis1-Induced Acute Myeloid Leukemia Blood. 128: 3935-3935. DOI: 10.1182/Blood.V128.22.3935.3935 |
0.344 |
|
| 2016 |
Müller SJ, Waldschmidt JM, Senger J, Wider D, Thomsen AR, Ihorst G, Duyster J, Hug MJ, Jung M, Wäsch R, Engelhardt M. Testing Novel Anti - Multiple Myeloma (MM) Agents in a Suitable Three-Dimensional (3D) Co-Culture Platform Blood. 128: 2109-2109. DOI: 10.1182/Blood.V128.22.2109.2109 |
0.336 |
|
| 2016 |
Kolbinger F, Koeneke E, Senger J, Heimburg T, Bayer T, Jung M, Sippl W, Marek M, Romier C, Gunkel N, Miller A, Sehr P, Witt O, Oehme I. Development of novel HDAC inhibitors to selectively co-inhibit HDAC8 and HDAC10 in childhood cancer Klinische PäDiatrie. 228. DOI: 10.1055/S-0036-1582523 |
0.453 |
|
| 2016 |
Galleano I, Schiedel M, Jung M, Madsen AS, Olsen CA. A Continuous, Fluorogenic Sirtuin 2 Deacylase Assay: Substrate Screening and Inhibitor Evaluation Journal of Medicinal Chemistry. 59: 1021-1031. DOI: 10.1021/acs.jmedchem.5b01532 |
0.701 |
|
| 2016 |
Mathew NR, Baumgartner F, Waterhouse M, Müller TA, Schmitt-Gräff A, Weber A, Osswald L, Hanke K, Solsona ST, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, ... ... Jung M, et al. Sorafenib Promotes Graft-Versus-Leukemia Activity in Mice and Humans through IL-15 Production in Leukemia Cells Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.389 |
0.668 |
|
| 2015 |
Simon RP, Robaa D, Alhalabi Z, Sippl W, Jung M. KATching-up on Small Molecule Modulators of Lysine Acetyltransferases. Journal of Medicinal Chemistry. PMID 26701186 DOI: 10.1021/Acs.Jmedchem.5B01502 |
0.448 |
|
| 2015 |
Schiedel M, Rumpf T, Karaman B, Lehotzky A, Oláh J, Gerhardt S, Ovádi J, Sippl W, Einsle O, Jung M. Aminothiazoles as potent and selective Sirt2 inhibitors - a structure-activity relationship study. Journal of Medicinal Chemistry. PMID 26696402 DOI: 10.1021/Acs.Jmedchem.5B01517 |
0.766 |
|
| 2015 |
Senger J, Melesina J, Marek M, Romier C, Oehme I, Witt O, Sippl W, Jung M. Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors. Journal of Medicinal Chemistry. PMID 26653328 DOI: 10.1021/Acs.Jmedchem.5B01493 |
0.505 |
|
| 2015 |
Rumpf T, Gerhardt S, Einsle O, Jung M. Seeding for sirtuins: microseed matrix seeding to obtain crystals of human Sirt3 and Sirt2 suitable for soaking. Acta Crystallographica. Section F, Structural Biology Communications. 71: 1498-510. PMID 26625292 DOI: 10.1107/S2053230X15019986 |
0.331 |
|
| 2015 |
Rüger N, Roatsch M, Emmrich T, Franz H, Schüle R, Jung M, Link A. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A. Chemmedchem. 10: 1875-83. PMID 26337137 DOI: 10.1002/Cmdc.201500335 |
0.443 |
|
| 2015 |
Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions. Trends in Pharmacological Sciences. 36: 481-92. PMID 26013035 DOI: 10.1016/J.Tips.2015.04.013 |
0.455 |
|
| 2015 |
Marek M, Oliveira G, Pierce RJ, Jung M, Sippl W, Romier C. Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives. Future Medicinal Chemistry. 7: 783-800. PMID 25996070 DOI: 10.4155/Fmc.15.25 |
0.41 |
|
| 2015 |
Lancelot J, Cabezas-Cruz A, Caby S, Marek M, Schultz J, Romier C, Sippl W, Jung M, Pierce RJ. Schistosome sirtuins as drug targets. Future Medicinal Chemistry. 7: 765-82. PMID 25996069 DOI: 10.4155/Fmc.15.24 |
0.361 |
|
| 2015 |
Rapino F, Abhari B, Jung M, Fulda S. NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. Cell Death and Disease. 6. PMID 25766331 DOI: 10.1038/Cddis.2014.584 |
0.327 |
|
| 2015 |
Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, Oláh J, Ladwein KI, Schmidtkunz K, Gajer M, Pannek M, Steegborn C, Sinclair DA, Gerhardt S, Ovádi J, ... ... Jung M, et al. Selective Sirt2 inhibition by ligand-induced rearrangement of the active site. Nature Communications. 6: 6263. PMID 25672491 DOI: 10.1038/Ncomms7263 |
0.755 |
|
| 2015 |
Di Fruscia P, Zacharioudakis E, Liu C, Moniot S, Laohasinnarong S, Khongkow M, Harrison IF, Koltsida K, Reynolds CR, Schmidtkunz K, Jung M, Chapman KL, Steegborn C, Dexter DT, Sternberg MJ, et al. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model. Chemmedchem. 10: 69-82. PMID 25395356 DOI: 10.1002/Cmdc.201402431 |
0.457 |
|
| 2015 |
Schiedel M, Marek M, Lancelot J, Karaman B, Almlöf I, Schultz J, Sippl W, Pierce RJ, Romier C, Jung M. Fluorescence-based screening assays for the NAD⁺-dependent histone deacetylase smSirt2 from Schistosoma mansoni. Journal of Biomolecular Screening. 20: 112-21. PMID 25325257 DOI: 10.1177/1087057114555307 |
0.753 |
|
| 2015 |
Keller A, Waldschmidt JM, Wider D, Jakobs D, Möller M, Reinhardt H, Pantic M, Grishina O, Ihorst G, May AM, Frey A, Kohlweyer U, Duyster J, Jung M, Engelhardt M, et al. Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD) Blood. 126: 4260-4260. DOI: 10.1182/Blood.V126.23.4260.4260 |
0.304 |
|
| 2015 |
Schulz-Fincke J, Schmitt ML, Carlino L, Haydn T, Willmann D, Metzger E, Fulda S, Schüle R, Sippl W, Jung M. Abstract B81: Analogues of the chromenone namoline as inhibitors of lysine specific demethylase 1 (LSD1) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B81 |
0.471 |
|
| 2015 |
Jung M, Chakrabarti A, Heimbach T, Sippl W, Marek M, Romier C, Oehme I, Witt O. Abstract B80: New inhibitors of histone deacetylase 8 (HDAC8) as anticancer agents Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B80 |
0.49 |
|
| 2015 |
Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo Oncogenesis. 4. DOI: 10.1038/oncsis.2014.51 |
0.303 |
|
| 2015 |
Göbel P, Ritterbusch F, Helms M, Bischof M, Harms K, Jung M, Meggers E. Probing chiral recognition of enzyme active sites with octahedral iridium(III) propeller complexes European Journal of Inorganic Chemistry. DOI: 10.1002/Ejic.201500087 |
0.335 |
|
| 2015 |
Rüger N, Roatsch M, Emmrich T, Franz H, Schüle R, Jung M, Link A. Inside Cover: Tetrazolylhydrazides as Selective Fragment‐Like Inhibitors of the JumonjiC‐Domain‐Containing Histone Demethylase KDM4A (ChemMedChem 11/2015) Chemmedchem. 10: 1770-1770. DOI: 10.1002/Cmdc.201500459 |
0.452 |
|
| 2015 |
Schiedel M, Rumpf T, Karaman B, Lehotzky A, Gerhardt S, Ovádi J, Sippl W, Einsle O, Jung M. Strukturbasierte Entwicklung einer Affinitätssonde für Sirtuin 2 Angewandte Chemie. 128: 2293-2297. DOI: 10.1002/Ange.201509843 |
0.678 |
|
| 2014 |
Kulandaivelu U, Chilakamari LM, Jadav SS, Rao TR, Jayaveera KN, Shireesha B, Hauser AT, Senger J, Marek M, Romier C, Jung M, Jayaprakash V. Hydroxamates of para-aminobenzoic acid as selective inhibitors of HDAC8. Bioorganic Chemistry. 57: 116-20. PMID 25462986 DOI: 10.1016/J.Bioorg.2014.08.005 |
0.397 |
|
| 2014 |
Kannan S, Melesina J, Hauser AT, Chakrabarti A, Heimburg T, Schmidtkunz K, Walter A, Marek M, Pierce RJ, Romier C, Jung M, Sippl W. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation. Journal of Chemical Information and Modeling. 54: 3005-19. PMID 25243797 DOI: 10.1021/Ci5004653 |
0.428 |
|
| 2014 |
Carneiro VC, de Abreu da Silva IC, Torres EJ, Caby S, Lancelot J, Vanderstraete M, Furdas SD, Jung M, Pierce RJ, Fantappié MR. Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. Plos Pathogens. 10: e1004116. PMID 24809504 DOI: 10.1371/Journal.Ppat.1004116 |
0.397 |
|
| 2014 |
Schmitt ML, Ladwein KI, Carlino L, Schulz-Fincke J, Willmann D, Metzger E, Schilcher P, Imhof A, Schüle R, Sippl W, Jung M. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate. Journal of Biomolecular Screening. 19: 973-978. PMID 24687155 DOI: 10.1177/1087057114529156 |
0.441 |
|
| 2014 |
Stolfa DA, Marek M, Lancelot J, Hauser AT, Walter A, Leproult E, Melesina J, Rumpf T, Wurtz JM, Cavarelli J, Sippl W, Pierce RJ, Romier C, Jung M. Molecular basis for the antiparasitic activity of a mercaptoacetamide derivative that inhibits histone deacetylase 8 (HDAC8) from the human pathogen schistosoma mansoni. Journal of Molecular Biology. 426: 3442-53. PMID 24657767 DOI: 10.1016/J.Jmb.2014.03.007 |
0.498 |
|
| 2014 |
Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. Cancer Biology & Therapy. 15: 742-57. PMID 24618845 DOI: 10.4161/Cbt.28469 |
0.444 |
|
| 2014 |
Wagner T, Robaa D, Sippl W, Jung M. Mind the methyl: Methyllysine binding proteins in epigenetic regulation Chemmedchem. 9: 466-483. PMID 24449612 DOI: 10.1002/Cmdc.201300422 |
0.391 |
|
| 2014 |
Slynko I, Scharfe M, Rumpf T, Eib J, Metzger E, Schüle R, Jung M, Sippl W. Virtual screening of PRK1 inhibitors: Ensemble docking, rescoring using binding free energy calculation and QSAR model development Journal of Chemical Information and Modeling. 54: 138-150. PMID 24377786 DOI: 10.1021/Ci400628Q |
0.398 |
|
| 2014 |
Rapino F, Jung M, Fulda S. BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways Oncogene. 33: 1713-1724. PMID 23644654 DOI: 10.1038/Onc.2013.110 |
0.359 |
|
| 2014 |
Falenczyk C, Schiedel M, Karaman B, Rumpf T, Kuzmanovic N, Grøtli M, Sippl W, Jung M, König B. Chromo-pharmacophores: Photochromic diarylmaleimide inhibitors for sirtuins Chemical Science. 5: 4794-4799. DOI: 10.1039/C4Sc01346H |
0.752 |
|
| 2014 |
Furdas SD, Hoffmann I, Robaa D, Herquel B, Malinka W, ?wi?tek P, Akhtar A, Sippl W, Jung M. Pyrido- and benzisothiazolones as inhibitors of histone acetyltransferases (HATs) Medchemcomm. 5: 1856-1862. DOI: 10.1039/C4Md00245H |
0.487 |
|
| 2013 |
Lucas X, Wohlwend D, Hügle M, Schmidtkunz K, Gerhardt S, Schüle R, Jung M, Einsle O, Günther S. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angewandte Chemie (International Ed. in English). 52: 14055-9. PMID 24272870 DOI: 10.1002/Anie.201307652 |
0.487 |
|
| 2013 |
Marek M, Kannan S, Hauser AT, Moraes Mourão M, Caby S, Cura V, Stolfa DA, Schmidtkunz K, Lancelot J, Andrade L, Renaud JP, Oliveira G, Sippl W, Jung M, Cavarelli J, et al. Structural Basis for the Inhibition of Histone Deacetylase 8 (HDAC8), a Key Epigenetic Player in the Blood Fluke Schistosoma mansoni Plos Pathogens. 9. PMID 24086136 DOI: 10.1371/Journal.Ppat.1003645 |
0.481 |
|
| 2013 |
Lancelot J, Caby S, Dubois-Abdesselem F, Vanderstraete M, Trolet J, Oliveira G, Bracher F, Jung M, Pierce RJ. Schistosoma mansoni Sirtuins: characterization and potential as chemotherapeutic targets. Plos Neglected Tropical Diseases. 7: e2428. PMID 24069483 DOI: 10.1371/Journal.Pntd.0002428 |
0.437 |
|
| 2013 |
Schmitt ML, Hauser AT, Carlino L, Pippel M, Schulz-Fincke J, Metzger E, Willmann D, Yiu T, Barton M, Schüle R, Sippl W, Jung M. Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity Journal of Medicinal Chemistry. 56: 7334-7342. PMID 24007511 DOI: 10.1021/Jm400792M |
0.474 |
|
| 2013 |
Hauser A, Gajer JM, Jung M. Nonradioactive in vitro assays for histone deacetylases. Methods of Molecular Biology. 981: 211-227. PMID 23381865 DOI: 10.1007/978-1-62703-305-3_17 |
0.434 |
|
| 2013 |
Carlino L, Schmitt ML, Jung M, Sippl W. Ligand-based and structure-based design of novel histone demethylase inhibitors Journal of Cheminformatics. 5: 41. DOI: 10.1186/1758-2946-5-S1-P41 |
0.493 |
|
| 2013 |
Lübke M, Jung M, Haufe G. New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity Journal of Fluorine Chemistry. 152: 144-156. DOI: 10.1016/J.Jfluchem.2013.03.011 |
0.387 |
|
| 2012 |
Maurer B, Rumpf T, Scharfe M, Stolfa DA, Schmitt ML, He W, Verdin E, Sippl W, Jung M. Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5. Acs Medicinal Chemistry Letters. 3: 1050-3. PMID 24900427 DOI: 10.1021/Ml3002709 |
0.501 |
|
| 2012 |
Di Fruscia P, Ho KK, Laohasinnarong S, Khongkow M, Kroll SH, Islam SA, Sternberg MJ, Schmidtkunz K, Jung M, Lam EW, Fuchter MJ. The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors. Medchemcomm. PMID 24340169 DOI: 10.1039/C2Md00290F |
0.452 |
|
| 2012 |
Stolfa DA, Einsle O, Sippl W, Jung M. Current trends in epigenetic drug discovery Future Medicinal Chemistry. 4: 2029-2037. PMID 23157236 DOI: 10.4155/Fmc.12.144 |
0.368 |
|
| 2012 |
Yasgar A, Furdas SD, Maloney DJ, Jadhav A, Jung M, Simeonov A. High-throughput 1,536-well fluorescence polarization assays for α(1)-acid glycoprotein and human serum albumin binding. Plos One. 7: e45594. PMID 23029124 DOI: 10.1371/Journal.Pone.0045594 |
0.343 |
|
| 2012 |
Rotili D, Tarantino D, Carafa V, Paolini C, Schemies J, Jung M, Botta G, Maro SD, Novellino E, Steinkühler C, Maria RD, Gallinari P, Altucci L, Mai A. Benzodeazaoxaflavins as Sirtuin Inhibitors with Antiproliferative Properties in Cancer Stem Cells Journal of Medicinal Chemistry. 55: 8193-8197. PMID 22931526 DOI: 10.1021/Jm301115R |
0.327 |
|
| 2012 |
Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. The role of histone demethylases in cancer therapy Molecular Oncology. 6: 683-703. PMID 22902149 DOI: 10.1016/J.Molonc.2012.07.004 |
0.446 |
|
| 2012 |
Wagner T, Jung M. New lysine methyltransferase drug targets in cancer. Nature Biotechnology. 30: 622-3. PMID 22781684 DOI: 10.1038/Nbt.2300 |
0.382 |
|
| 2012 |
Stolfa DA, Stefanachi A, Gajer JM, Nebbioso A, Altucci L, Cellamare S, Jung M, Carotti A. Design, synthesis, and biological evaluation of 2-aminobenzanilide derivatives as potent and selective HDAC inhibitors. Chemmedchem. 7: 1256-1266. PMID 22628266 DOI: 10.1002/Cmdc.201200193 |
0.495 |
|
| 2012 |
Köhler J, Erlenkamp G, Eberlin A, Rumpf T, Slynko I, Metzger E, Schüle R, Sippl W, Jung M. Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells Plos One. 7. PMID 22532837 DOI: 10.1371/Journal.Pone.0034973 |
0.412 |
|
| 2012 |
Hackanson B, Rimmele L, Benkißer M, Abdelkarim M, Fliegauf M, Jung M, Lübbert M. HDAC6 as a target for antileukemic drugs in acute myeloid leukemia. Leukemia Research. 36: 1055-1062. PMID 22464548 DOI: 10.1016/J.Leukres.2012.02.026 |
0.442 |
|
| 2012 |
Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schüle R, Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. International Journal of Cancer. Journal International Du Cancer. 131: 2704-9. PMID 22447389 DOI: 10.1002/Ijc.27555 |
0.449 |
|
| 2012 |
Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Archiv Der Pharmazie. 345: 7-21. PMID 22234972 DOI: 10.1002/Ardp.201100209 |
0.455 |
|
| 2012 |
Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayser S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. The Journal of Experimental Medicine. 209: 35-50. PMID 22231305 DOI: 10.1084/Jem.20110540 |
0.321 |
|
| 2012 |
Hauser AT, Bissinger EM, Metzger E, Repenning A, Bauer UM, Mai A, Schüle R, Jung M. Screening assays for epigenetic targets using native histones as substrates. Journal of Biomolecular Screening. 17: 18-26. PMID 21965113 DOI: 10.1177/1087057111423968 |
0.482 |
|
| 2012 |
Furdas SD, Shekfeh S, Kannan S, Sippl W, Jung M. Rhodanine carboxylic acids as novel inhibitors of histone acetyltransferases Medchemcomm. 3: 305-311. DOI: 10.1039/C2Md00211F |
0.498 |
|
| 2012 |
Uciechowska U, Schemies J, Scharfe M, Lawson M, Wichapong K, Jung M, Sippl W. Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD + dependent histone deacetylase Sirt2 Medchemcomm. 3: 167-173. DOI: 10.1039/C1Md00214G |
0.359 |
|
| 2012 |
Furdas SD, Carlino L, Sippl W, Jung M. Inhibition of bromodomain-mediated protein-protein interactions as a novel therapeutic strategy Medchemcomm. 3: 123-134. DOI: 10.1039/C1Md00201E |
0.459 |
|
| 2012 |
Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates Archiv Der Pharmazie. 345: 7-21. DOI: 10.1002/ardp.201100209 |
0.318 |
|
| 2011 |
Halley F, Reinshagen J, Ellinger B, Wolf M, Niles AL, Evans NJ, Kirkland TA, Wagner JM, Jung M, Gribbon P, Gul S. A bioluminogenic HDAC activity assay: validation and screening. Journal of Biomolecular Screening. 16: 1227-35. PMID 21832257 DOI: 10.1177/1087057111416004 |
0.439 |
|
| 2011 |
Hauser A, Jung M. Chemical probes: sharpen your epigenetic tools. Nature Chemical Biology. 7: 499-500. PMID 21769094 DOI: 10.1038/Nchembio.615 |
0.413 |
|
| 2011 |
Schiedel M, Jung M. [Dysregulation of histone acetylation as a molecular basis for the development of dementia]. Pharmazie in Unserer Zeit. 40: 297-9. PMID 21698626 DOI: 10.1002/Pauz.201190039 |
0.723 |
|
| 2011 |
Pesnot T, Kempter J, Schemies J, Pergolizzi G, Uciechowska U, Rumpf T, Sippl W, Jung M, Wagner GK. Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD) Journal of Medicinal Chemistry. 54: 3492-3499. PMID 21528845 DOI: 10.1021/Jm1013852 |
0.403 |
|
| 2011 |
Bissinger EM, Heinke R, Spannhoff A, Eberlin A, Metzger E, Cura V, Hassenboehler P, Cavarelli J, Schüle R, Bedford MT, Sippl W, Jung M. Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1 Bioorganic and Medicinal Chemistry. 19: 3717-3731. PMID 21440447 DOI: 10.1016/J.Bmc.2011.02.032 |
0.473 |
|
| 2011 |
Schlimme S, Hauser AT, Carafa V, Heinke R, Kannan S, Stolfa DA, Cellamare S, Carotti A, Altucci L, Jung M, Sippl W. Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors Chemmedchem. 6: 1193-1198. PMID 21416613 DOI: 10.1002/Cmdc.201100007 |
0.45 |
|
| 2011 |
Furdas SD, Shekfeh S, Bissinger EM, Wagner JM, Schlimme S, Valkov V, Hendzel M, Jung M, Sippl W. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors Bioorganic and Medicinal Chemistry. 19: 3678-3689. PMID 21353783 DOI: 10.1016/J.Bmc.2011.01.063 |
0.476 |
|
| 2011 |
Heinke R, Carlino L, Kannan S, Jung M, Sippl W. Computer- and structure-based lead design for epigenetic targets Bioorganic and Medicinal Chemistry. 19: 3605-3615. PMID 21316248 DOI: 10.1016/J.Bmc.2011.01.029 |
0.442 |
|
| 2011 |
Freitag M, Schemies J, Larsen T, El Gaghlab K, Schulz F, Rumpf T, Jung M, Link A. Synthesis and biological activity of splitomicin analogs targeted at human NAD(+)-dependent histone deacetylases (sirtuins). Bioorganic & Medicinal Chemistry. 19: 3669-77. PMID 21315612 DOI: 10.1016/J.Bmc.2011.01.026 |
0.497 |
|
| 2011 |
Maurer B, Mathias U, Papatheodorou P, Shekfeh S, Orth J, Jank T, Schwan C, Sippl W, Aktories K, Jung M. From cosubstrate similarity to inhibitor diversity-Inhibitors of ADP-ribosyltransferases from kinase inhibitor screening Molecular Biosystems. 7: 799-808. PMID 21132207 DOI: 10.1039/C0Mb00151A |
0.449 |
|
| 2011 |
Scharfe M, Maurer B, Aktories K, Jung M, Sippl W. Docking and virtual screening of novel inhibitors for mono-ADP-ribosylating toxins Journal of Cheminformatics. 3. DOI: 10.1186/1758-2946-3-S1-P38 |
0.441 |
|
| 2011 |
Kelter G, Metz T, Diana S, Jung M, Fiebig H. Abstract C186: In vitro profiling and compare analysis of the novel HDAC6-selective inhibitor ST80 in 42 human tumor cell lines. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C186 |
0.457 |
|
| 2010 |
Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics. 1: 117-136. PMID 21258646 DOI: 10.1007/S13148-010-0012-4 |
0.445 |
|
| 2010 |
Bissinger E, Jung M. No Taste for Methyl: Methylation Sensitive Proteolysis in Drug Screening Chemistry & Biology. 17: 677-678. PMID 20659678 DOI: 10.1016/J.Chembiol.2010.07.001 |
0.382 |
|
| 2010 |
Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4217-25. PMID 20601444 DOI: 10.1158/1078-0432.Ccr-10-0777 |
0.339 |
|
| 2010 |
Lawson M, Uciechowska U, Schemies J, Rumpf T, Jung M, Sippl W. Inhibitors to understand molecular mechanisms of NAD+-dependent deacetylases (sirtuins) Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms. 1799: 726-739. PMID 20601279 DOI: 10.1016/J.Bbagrm.2010.06.003 |
0.473 |
|
| 2010 |
Wagner JM, Bug G, Jung M. [Valproic acid as a histone deacetylase inhibitor. New application for a well-known drug]. Pharmazie in Unserer Zeit. 39: 197-203. PMID 20425769 DOI: 10.1002/Pauz.201000366 |
0.374 |
|
| 2010 |
Wagner JM, Jung M. [New approach to determine the pharmacodynamic effects of histone deacetylases inhibitors]. Pharmazie in Unserer Zeit. 39: 173-4. PMID 20425766 DOI: 10.1002/Pauz.201090027 |
0.413 |
|
| 2010 |
Rotili D, Tarantino D, Carafa V, Lara E, Meade S, Botta G, Nebbioso A, Schemies J, Jung M, Kazantsev AG, Esteller M, Fraga MF, Altucci L, Mai A. Identification of tri- and tetracyclic pyrimidinediones as sirtuin inhibitors. Chemmedchem. 5: 674-7. PMID 20391556 DOI: 10.1002/Cmdc.201000030 |
0.418 |
|
| 2010 |
Gutiérrez M, Tidgewell K, Capson TL, Engene N, Almanza A, Schemies J, Jung M, Gerwick WH. Malyngolide dimer, a bioactive symmetric cyclodepside from the panamanian marine cyanobacterium Lyngbya majuscula. Journal of Natural Products. 73: 709-11. PMID 20158242 DOI: 10.1021/Np9005184 |
0.327 |
|
| 2010 |
Huber K, Schemies J, Uciechowska U, Wagner JM, Rumpf T, Lewrick F, Süss R, Sippl W, Jung M, Bracher F. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins) Journal of Medicinal Chemistry. 53: 1383-1386. PMID 20030343 DOI: 10.1021/Jm901055U |
0.464 |
|
| 2010 |
Schemies J, Uciechowska U, Sippl W, Jung M. NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets Medicinal Research Reviews. 30: 861-889. PMID 19824050 DOI: 10.1002/Med.20178 |
0.454 |
|
| 2010 |
Kim J, Bähr M, Wagner J, Nicola GD, Rüfer C, Jung M, Iori R, Gerhäuser C. Abstract A62: Increased histone acetylation, but no inhibition of HDAC activity, by kale sprout intervention in a human prostate cancer xenograft model Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A62 |
0.387 |
|
| 2010 |
Bissinger EM, Heinke R, Sippl W, Jung M. Targeting epigenetic modifiers: Inhibitors of histone methyltransferases Medchemcomm. 1: 114-124. DOI: 10.1039/C0Md00062K |
0.424 |
|
| 2010 |
O'MEARA JA, GARDEE N, JUNG M, BEN RN, DURST T. ChemInform Abstract: Enantioselective Synthesis of β-Dibenzylamino Alcohols via a Dynamic Kinetic Resolution of α-Halo Acids. Cheminform. 29: no-no. DOI: 10.1002/CHIN.199834116 |
0.519 |
|
| 2010 |
HANEFELD W, JUNG M. ChemInform Abstract: Selective Synthesis of ortho-Disubstituted Tetrahydroanthracenes with Retinoid Structure. Cheminform. 25: no-no. DOI: 10.1002/CHIN.199435227 |
0.57 |
|
| 2010 |
HANEFELD W, JUNG M. ChemInform Abstract: Synthesis of a Retinoid with Acetylaryltetrahydronaphthene Structure and an Unusual Cleavage of an ortho-Acetyltriflate. Cheminform. 25: no-no. DOI: 10.1002/CHIN.199422260 |
0.552 |
|
| 2010 |
HANEFELD W, JUNG M. ChemInform Abstract: Synthesis of Retinoids with Aryltetrahydroanthracene Structure. Cheminform. 25: no-no. DOI: 10.1002/CHIN.199420291 |
0.546 |
|
| 2009 |
Spannhoff A, Hauser AT, Heinke R, Sippl W, Jung M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors Chemmedchem. 4: 1568-1582. PMID 19739196 DOI: 10.1002/Cmdc.200900301 |
0.443 |
|
| 2009 |
Gutiérrez M, Andrianasolo EH, Shin WK, Goeger DE, Yokochi A, Schemies J, Jung M, France D, Cornell-Kennon S, Lee E, Gerwick WH. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. The Journal of Organic Chemistry. 74: 5267-75. PMID 19572575 DOI: 10.1021/Jo900578J |
0.346 |
|
| 2009 |
Hauser AT, Jung M. Assays for histone deacetylases Current Topics in Medicinal Chemistry. 9: 227-234. PMID 19355987 DOI: 10.2174/156802609788085269 |
0.438 |
|
| 2009 |
Schemies J, Sippl W, Jung M. Histone deacetylase inhibitors that target tubulin Cancer Letters. 280: 222-232. PMID 19268440 DOI: 10.1016/J.Canlet.2009.01.040 |
0.441 |
|
| 2009 |
Wang Z, Chen C, Finger SN, Kwajah S, Jung M, Schwarz H, Swanson N, Lareu FF, Raghunath M. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? The European Respiratory Journal. 34: 145-55. PMID 19224893 DOI: 10.1183/09031936.00084808 |
0.319 |
|
| 2009 |
Agbor-Enoh S, Seudieu C, Davidson E, Dritschilo A, Jung M. Novel Inhibitor of Plasmodium Histone Deacetylase That Cures P. berghei-Infected Mice Antimicrobial Agents and Chemotherapy. 53: 1727-1734. PMID 19223622 DOI: 10.1128/Aac.00729-08 |
0.312 |
|
| 2009 |
Zhao W, Dai F, Bonafede A, Schafer S, Jung M, Yusuf F, Gamel AJ, Wang J, Brand-Saberi B. Histone deacetylase inhibitor, trichostatin A, affects gene expression patterns during morphogenesis of chicken limb buds in vivo. Cells, Tissues, Organs. 190: 121-34. PMID 19147985 DOI: 10.1159/000193397 |
0.361 |
|
| 2009 |
Schäfer S, Saunders L, Schlimme S, Valkov V, Wagner JM, Kratz F, Sippl W, Verdin E, Jung M. Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors Chemmedchem. 4: 283-290. PMID 19090524 DOI: 10.1002/Cmdc.200800196 |
0.501 |
|
| 2009 |
Heinke R, Spannhoff A, Meier R, Trojer P, Bauer I, Jung M, Sippl W. Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors Chemmedchem. 4: 69-77. PMID 19085993 DOI: 10.1002/Cmdc.200800301 |
0.478 |
|
| 2009 |
Spannhoff A, Sippl W, Jung M. Cancer treatment of the future: Inhibitors of histone methyltransferases International Journal of Biochemistry and Cell Biology. 41: 4-11. PMID 18773966 DOI: 10.1016/J.Biocel.2008.07.024 |
0.434 |
|
| 2009 |
Hackanson BW, Rimmele L, Jung M, Lübbert M. Selective HDAC6 Inhibition and Antileukemic Activity of the Novel HDAC Inhibitor ST80 in Myeloid Leukemia Cell Lines. Blood. 114: 4808-4808. DOI: 10.1182/Blood.V114.22.4808.4808 |
0.457 |
|
| 2008 |
Uciechowska U, Schemies J, Neugebauer RC, Huda EM, Schmitt ML, Meier R, Verdin E, Jung M, Sippl W. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. Chemmedchem. 3: 1965-76. PMID 18985648 DOI: 10.1002/Cmdc.200800104 |
0.453 |
|
| 2008 |
Hauser A, Jung M. Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention Planta Medica. 74: 1593-1601. PMID 18704881 DOI: 10.1055/S-2008-1081347 |
0.388 |
|
| 2008 |
Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC. Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6. Molecular Cancer Research : McR. 6: 1250-8. PMID 18644987 DOI: 10.1158/1541-7786.Mcr-07-2110 |
0.432 |
|
| 2008 |
Neugebauer RC, Sippl W, Jung M. Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Current Pharmaceutical Design. 14: 562-73. PMID 18336301 DOI: 10.2174/138161208783885380 |
0.487 |
|
| 2008 |
Neugebauer RC, Uchiechowska U, Meier R, Hruby H, Valkov V, Verdin E, Sippl W, Jung M. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. Journal of Medicinal Chemistry. 51: 1203-13. PMID 18269226 DOI: 10.1021/Jm700972E |
0.506 |
|
| 2008 |
Schäfer S, Saunders L, Eliseeva E, Velena A, Jung M, Schwienhorst A, Strasser A, Dickmanns A, Ficner R, Schlimme S, Sippl W, Verdin E, Jung M. Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorganic & Medicinal Chemistry. 16: 2011-33. PMID 18054239 DOI: 10.1016/J.Bmc.2007.10.092 |
0.48 |
|
| 2008 |
Fenic I, Hossain HM, Sonnack V, Tchatalbachev S, Thierer F, Trapp J, Failing K, Edler KS, Bergmann M, Jung M, Chakraborty T, Steger K. In vivo application of histone deacetylase inhibitor trichostatin-A impairs murine male meiosis Journal of Andrology. 29: 172-185. PMID 18046049 DOI: 10.2164/Jandrol.107.003848 |
0.394 |
|
| 2007 |
Arts J, Angibaud P, Mariën A, Floren W, Janssens B, King P, van Dun J, Janssen L, Geerts T, Tuman RW, Johnson DL, Andries L, Jung M, Janicot M, van Emelen K. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. British Journal of Cancer. 97: 1344-53. PMID 18000499 DOI: 10.1038/Sj.Bjc.6604025 |
0.408 |
|
| 2007 |
Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Molecular Cancer Therapeutics. 6: 2391-2398. PMID 17876038 DOI: 10.1158/1535-7163.Mct-07-0159 |
0.481 |
|
| 2007 |
Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). Chemmedchem. 2: 1419-31. PMID 17628866 DOI: 10.1002/Cmdc.200700003 |
0.489 |
|
| 2007 |
Spannhoff A, Machmur R, Heinke R, Trojer P, Bauer I, Brosch G, Schüle R, Hanefeld W, Sippl W, Jung M. A novel arginine methyltransferase inhibitor with cellular activity. Bioorganic & Medicinal Chemistry Letters. 17: 4150-3. PMID 17570663 DOI: 10.1016/J.Bmcl.2007.05.088 |
0.695 |
|
| 2007 |
Mathias U, Jung M. Determination of drug-serum protein interactions via fluorescence polarization measurements. Analytical and Bioanalytical Chemistry. 388: 1147-1156. PMID 17554529 DOI: 10.1007/S00216-007-1351-7 |
0.302 |
|
| 2007 |
Spannhoff A, Heinke R, Bauer I, Trojer P, Metzger E, Gust R, Schüle R, Brosch G, Sippl W, Jung M. Target-based approach to inhibitors of histone arginine methyltransferases. Journal of Medicinal Chemistry. 50: 2319-25. PMID 17432842 DOI: 10.1021/Jm061250E |
0.495 |
|
| 2007 |
Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood International Journal of Cancer. 120: 1787-1794. PMID 17230517 DOI: 10.1002/Ijc.22401 |
0.346 |
|
| 2007 |
Steger K, Fenic I, Hossain HM, Sonnack V, Tchatalbachev S, Trapp J, Failing K, Bergmann M, Jung M, Chakraborty T, Weidner W. 1859: The Histone Deycetylase Inhibitor Trichostatin-a Arrests Meiosis in Male Mice The Journal of Urology. 177: 617-617. DOI: 10.1016/S0022-5347(18)32032-9 |
0.368 |
|
| 2006 |
Trapp J, Jochum A, Meier R, Saunders L, Marshall B, Kunick C, Verdin E, Goekjian P, Sippl W, Jung M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. Journal of Medicinal Chemistry. 49: 7307-16. PMID 17149860 DOI: 10.1021/Jm060118B |
0.465 |
|
| 2006 |
Trapp J, Jung M. The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. Current Drug Targets. 7: 1553-1560. PMID 17100594 DOI: 10.2174/1389450110607011553 |
0.432 |
|
| 2005 |
Cao H, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce γ gene expression in vivo Experimental Hematology. 33: 1443-1449. PMID 16338486 DOI: 10.1016/J.Exphem.2005.08.007 |
0.362 |
|
| 2005 |
Heltweg B, Trapp J, Jung M. In vitro assays for the determination of histone deacetylase activity. Methods. 36: 332-337. PMID 16087348 DOI: 10.1016/J.Ymeth.2005.03.003 |
0.464 |
|
| 2005 |
Schäfer S, Jung M. Chromatin modifications as targets for new anticancer drugs. Archiv Der Pharmazie. 338: 347-357. PMID 16041839 DOI: 10.1002/Ardp.200500984 |
0.445 |
|
| 2005 |
Wittich S, Scherf H, Xie C, Heltweg B, Dequiedt F, Verdin E, Gerhäuser C, Jung M. Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines Anti-Cancer Drugs. 16: 635-643. PMID 15930892 DOI: 10.1097/00001813-200507000-00008 |
0.492 |
|
| 2005 |
Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. Plos Biology. 3: e41. PMID 15719057 DOI: 10.1371/Journal.Pbio.0030041 |
0.3 |
|
| 2004 |
Heltweg B, Dequiedt F, Marshall BL, Brauch C, Yoshida M, Nishino N, Verdin E, Jung M. Subtype selective substrates for histone deacetylases Journal of Medicinal Chemistry. 47: 5235-5243. PMID 15456267 DOI: 10.1021/Jm0497592 |
0.429 |
|
| 2004 |
Zhang Y, Jung M, Dritschilo A, Jung M. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiation Research. 161: 667-674. PMID 15161353 DOI: 10.1667/Rr3192 |
0.377 |
|
| 2004 |
Cao H, Stamatoyannopoulos G, Jung M. Induction of human γ globin gene expression by histone deacetylase inhibitors Blood. 103: 701-709. PMID 12920038 DOI: 10.1182/Blood-2003-02-0478 |
0.434 |
|
| 2004 |
Klan N, Seuter S, Schnur N, Jung M, Steinhilber D. Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biological Chemistry. 384: 777-85. PMID 12817474 DOI: 10.1515/BC.2003.086 |
0.317 |
|
| 2003 |
Hirao M, Posakony J, Nelson M, Hruby H, Jung M, Simon JA, Bedalov A. Identification of selective inhibitors of NAD+-dependent deacetylases using phenotypic screens in yeast. The Journal of Biological Chemistry. 278: 52773-82. PMID 14534292 DOI: 10.1074/Jbc.M308966200 |
0.319 |
|
| 2003 |
Heltweg B, Jung M. A homogeneous nonisotopic histone deacetylase activity assay. Journal of Biomolecular Screening. 8: 89-95. PMID 12855002 DOI: 10.1177/1087057102239644 |
0.463 |
|
| 2003 |
Heltweg B, Dequiedt F, Verdin E, Jung M. Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases Analytical Biochemistry. 319: 42-48. PMID 12842105 DOI: 10.1016/S0003-2697(03)00276-8 |
0.449 |
|
| 2003 |
Skarpidi E, Cao H, Heltweg B, White BF, Marhenke RL, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Experimental Hematology. 31: 197-203. PMID 12644016 DOI: 10.1016/S0301-472X(02)01030-5 |
0.347 |
|
| 2003 |
Jung M. Homogeneous non-isotopic assays for histone deacetylase activity Expert Opinion On Therapeutic Patents. 13: 935-935. DOI: 10.1517/13543776.13.6.935 |
0.453 |
|
| 2002 |
Heltweg B, Jung M. Eosin Y as an internal standard for a plate reader-based quantitation of a histone deacetylase substrate. Archiv Der Pharmazie. 335: 296-300. PMID 12210773 DOI: 10.1002/1521-4184(200208)335:6<296::Aid-Ardp296>3.0.Co;2-6 |
0.442 |
|
| 2002 |
Wittich S, Scherf H, Xie C, Brosch G, Loidl P, Gerhäuser C, Jung M. Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. Journal of Medicinal Chemistry. 45: 3296-3309. PMID 12109913 DOI: 10.1021/Jm0208119 |
0.489 |
|
| 2002 |
Heltweg B, Jung M. A microplate reader-based nonisotopic histone deacetylase activity assay. Analytical Biochemistry. 302: 175-183. PMID 11878795 DOI: 10.1006/Abio.2001.5542 |
0.461 |
|
| 2002 |
Remiszewski SW, Sambucetti LC, Atadja P, Bair KW, Cornell WD, Green MA, Howell KL, Jung M, Kwon P, Trogani N, Walker H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. Journal of Medicinal Chemistry. 45: 753-7. PMID 11831887 DOI: 10.1021/Jm015568C |
0.443 |
|
| 2001 |
Jung M. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy Mini Reviews in Medicinal Chemistry. 1: 399-407. PMID 12369965 DOI: 10.2174/1389557013406747 |
0.302 |
|
| 2001 |
Jung M. Inhibitors of histone deacetylase as new anticancer agents Current Medicinal Chemistry. 8: 1505-1511. PMID 11562279 DOI: 10.2174/0929867013372058 |
0.502 |
|
| 2001 |
Hoffmann K, Heltweg B, Jung M. Improvement and validation of the fluorescence-based histone deacetylase assay using an internal standard. Archiv Der Pharmazie. 334: 248-252. PMID 11512276 DOI: 10.1002/1521-4184(200107)334:7<248::Aid-Ardp248>3.0.Co;2-K |
0.448 |
|
| 2001 |
Hoffmann K, Söll RM, Beck-Sickinger ‡aAG, Jung M. Fluorescence-labeled octapeptides as substrates for histone deacetylase. Bioconjugate Chemistry. 12: 51-55. PMID 11170365 DOI: 10.1021/Bc000051L |
0.45 |
|
| 2000 |
Jung M. Histone deacetylase inhibitors as new agents for the prevention and treatment of cancer Pharmazie in Unserer Zeit. 29: 385-388. PMID 11199916 DOI: 10.1002/1615-1003(200012)29:6<385::Aid-Pauz385>3.0.Co;2-3 |
0.407 |
|
| 2000 |
Jung M, Wahl AF, Neupert W, Geisslinger G, Senter PD. Synthesis and Activity of Fluorinated Derivatives of Sulindac Sulphide and Sulindac Sulphone Pharmacy and Pharmacology Communications. 6: 217-221. DOI: 10.1211/146080800128735926 |
0.35 |
|
| 2000 |
Schmidt K, Jung M, Keilitz R, Schnurr B, Gust R. Acetylenehexacarbonyldicobalt complexes, a novel class of antitumor drugs Inorganica Chimica Acta. 306: 6-16. DOI: 10.1016/S0020-1693(00)00139-0 |
0.301 |
|
| 1999 |
Jung M, Brosch G, Kölle D, Scherf H, Gerhäuser C, Loidl P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. Journal of Medicinal Chemistry. 42: 4669-4679. PMID 10579829 DOI: 10.1021/Jm991091H |
0.461 |
|
| 1999 |
Schmidt K, Gust R, Jung M. Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Archiv Der Pharmazie. 332: 353-357. PMID 10575368 DOI: 10.1002/(Sici)1521-4184(199910)332:10<353::Aid-Ardp353>3.0.Co;2-X |
0.434 |
|
| 1999 |
Hoffmann K, Jung M, Brosch G, Loidl P. A non-isotopic assay for histone deacetylase activity Nucleic Acids Research. 27: 2057-2058. PMID 10198441 DOI: 10.1093/Nar/27.9.2057 |
0.505 |
|
| 1998 |
O'Meara JA, Gardee N, Jung M, Ben RN, Durst T. Enantioselective Synthesis of β-Dibenzylamino Alcohols via a Dynamic Kinetic Resolution of α-Halo Acids The Journal of Organic Chemistry. 63: 3117-3119. DOI: 10.1021/Jo9712714 |
0.663 |
|
| 1997 |
Jung M, Hoffmann K, Brosch G, Loidl P. Analogues of trichosтatin a and trapoxin B as histone deacetylase inhibitors Bioorganic & Medicinal Chemistry Letters. 7: 1655-1658. DOI: 10.1016/S0960-894X(97)00284-9 |
0.502 |
|
| 1995 |
O'Meara JA, Jung M, Durst T. Dynamic kinetic resolution of racemic α-halo acids via a chiral imidazolidinone auxiliary Tetrahedron Letters. 36: 2559-2562. DOI: 10.1016/0040-4039(95)00339-E |
0.536 |
|
| 1994 |
Hanefeld W, Jung M. Synthesis of pentacyclic retinoids Tetrahedron. 50: 2459-2468. DOI: 10.1016/S0040-4020(01)86962-3 |
0.577 |
|
| 1994 |
Durst T, Ben R, Jung M. FC43 the synthesis of α-amino acid esters using α-hydroxy amides as chiral auxiliaries European Journal of Pharmaceutical Sciences. 2: 111. DOI: 10.1016/0928-0987(94)90152-X |
0.647 |
|
| Show low-probability matches. |
